[{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"National Pediatric Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"DeuteRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterium-stabilized S-avadomide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Salarius Pharmaceuticals","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Salarius","highestDevelopmentStatusID":"4","companyTruncated":"Salarius Pharmaceuticals \/ Salarius"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"VolitionRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ VolitionRx","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ VolitionRx"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Oregon Health & Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Oregon Health & Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Oregon Health & Sciences"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avadomide","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SP-3204","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Decoy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"SP-3164","moa":"CRBN","graph1":"Oncology","graph2":"Phase I","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Decoy Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Salarius Pharmaceuticals \/ Decoy Therapeutics"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Salarius Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
